RxDoctor Payments Data

Peter Unkovic, DO

Advanced Heart Failure and Transplant Cardiology · Zanesville, OHNPI 1114269180

Payments from drug & device makers

What this record shows

This record is dominated by grants: $15,000 of the $19,331 with a category attached, or 77.6%. Medtronic accounts for 78.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2019 at $15,301 and has fallen 96.8% since, to $490 in 2025.

$19,331in general payments, 2019–2025

Across 167 payments — averaging $115.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$15K
  • Boston Scientific$2K
  • Amgen$429
  • Novartis$419
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$349
  • AstraZeneca$327
  • plus $959 from 13 others

What the payments were for

  • Grants$15,00078%
  • Travel & lodging$8464%
  • Food & beverage$3,47218%
  • Education$140%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$19,331 in reported general payments places this provider in the 70th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.

See all advanced heart failure and transplant cardiology providers in Ohio

Medicare billing

Part B allowed, 2024
$65,003
Medicare patients
477
Services billed
986

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VyndamaxTafamidis22$593,696
EliquisApixaban127$126,332
EntrestoSacubitril/Valsartan95$101,091
FarxigaDapagliflozin Propanediol33$27,584
XareltoRivaroxaban27$23,391
JardianceEmpagliflozin12$13,177
Metoprolol Succinate213$3,120
Atorvastatin Calcium79$1,561
Rosuvastatin Calcium74$1,324
Carvedilol77$1,188
Torsemide73$934
Valsartan19$900
Nifedipine ErNifedipine55$864
Spironolactone154$836
Losartan Potassium54$755

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerVyndamax, Eliquis$250$720,029149 claims
NovartisEntresto$419$101,09195 claims
AstraZenecaFarxiga$327$27,58433 claims
Johnson & JohnsonXarelto$124$23,39127 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.

Other advanced heart failure and transplant cardiology in Zanesville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →